Interestingly, dexamethasone has been demonstrated to lower the 28-day mortality rate among patients hospitalized with COVID-19 receiving respiratory support [146], providing a clinical benefit that could also be explained by the inhibition of TLR4-mediated activation in the endothelium. This evidence concerns the gene TLR4 and COVID-19.